Sarepta Therapeutics, Inc. - Product Pipeline Review - 2015

Published: Jun, 2015 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Sarepta Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Sarepta Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sarepta Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Sarepta Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Sarepta Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Sarepta Therapeutics, Inc.'s pipeline products

Reasons to buy

- Evaluate Sarepta Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Sarepta Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Sarepta Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Sarepta Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sarepta Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Sarepta Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Sarepta Therapeutics, Inc. Snapshot 7
Sarepta Therapeutics, Inc. Overview 7
Key Information 7
Key Facts 7
Sarepta Therapeutics, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Sarepta Therapeutics, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Sarepta Therapeutics, Inc. - Pipeline Products Glance 13
Sarepta Therapeutics, Inc. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Sarepta Therapeutics, Inc. - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Sarepta Therapeutics, Inc. - Early Stage Pipeline Products 15
IND/CTA Filed Products/Combination Treatment Modalities 15
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Sarepta Therapeutics, Inc. - Drug Profiles 18
eteplirsen 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
SRP-4053 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
AVI-7288 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
radavirsen 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
SRP-4045 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PMO-25 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SRP-4044 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SRP-4050 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SRP-4052 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Antisense Oligonucleotide for Acinetobacter baumannii Infections 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Antisense Oligonucleotide for Drug Resistant Pseudomonas Aeruginosa Infections 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Antisense Oligonucleotide for Methicillin Resistant Staphylococcus Aureus Infections 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Antisense Oligonucleotide for Rare Disease 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Antisense Oligonucleotide to Activate Lamin A for Progeria 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Antisense Oligonucleotides for Infectious Diseases 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Bacterial PPMO 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SRP-4008 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
SRP-4055 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Viral PMO-X 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Sarepta Therapeutics, Inc. - Pipeline Analysis 46
Sarepta Therapeutics, Inc. - Pipeline Products by Target 46
Sarepta Therapeutics, Inc. - Pipeline Products by Route of Administration 47
Sarepta Therapeutics, Inc. - Pipeline Products by Molecule Type 48
Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action 49
Sarepta Therapeutics, Inc. - Recent Pipeline Updates 50
Sarepta Therapeutics, Inc. - Dormant Projects 61
Sarepta Therapeutics, Inc. - Discontinued Pipeline Products 62
Discontinued Pipeline Product Profiles 62
AVI-4065 62
AVI-6002 62
AVI-7537 62
Sarepta Therapeutics, Inc. - Company Statement 63
Sarepta Therapeutics, Inc. - Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables

Sarepta Therapeutics, Inc., Key Information 7
Sarepta Therapeutics, Inc., Key Facts 7
Sarepta Therapeutics, Inc. - Pipeline by Indication, 2015 9
Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2015 11
Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 12
Sarepta Therapeutics, Inc. - Phase III, 2015 13
Sarepta Therapeutics, Inc. - Phase I, 2015 14
Sarepta Therapeutics, Inc. - IND/CTA Filed, 2015 15
Sarepta Therapeutics, Inc. - Preclinical, 2015 16
Sarepta Therapeutics, Inc. - Discovery, 2015 17
Sarepta Therapeutics, Inc. - Pipeline by Target, 2015 46
Sarepta Therapeutics, Inc. - Pipeline by Route of Administration, 2015 47
Sarepta Therapeutics, Inc. - Pipeline by Molecule Type, 2015 48
Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 49
Sarepta Therapeutics, Inc. - Recent Pipeline Updates, 2015 50
Sarepta Therapeutics, Inc. - Dormant Developmental Projects,2015 61
Sarepta Therapeutics, Inc. - Discontinued Pipeline Products, 2015 62
Sarepta Therapeutics, Inc., Other Locations 66
Sarepta Therapeutics, Inc., Subsidiaries 66